drugset
drugset / Trial / NCT05584800

Study of ZGGS18 in Patients With Advanced Solid Tumors

NCT05584800 ↗

Phase 1/2 Recruiting 222 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

A clinical study to assess dose escalation, tolerance, safety, pharmacokinetics, and multi cohort expansion of ZGGS18 in patients with advanced solid tumors

Timeline

Start
2022-11-15
Primary completion
2026-11-01
Completion
2026-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ZGGS18 Unknown 0.3 mg/kg Intravenous
Subject ZGGS18 Unknown 1 mg/kg Intravenous
Subject ZGGS18 Unknown 3 mg/kg Intravenous
Subject ZGGS18 Unknown 6 mg/kg Intravenous
Subject ZGGS18 Unknown 10 mg/kg Intravenous
Subject ZGGS18 Unknown 15 mg/kg Intravenous
Subject ZGGS18 Unknown 20 mg/kg Intravenous

Indications

No indication recorded.